Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors
about
Why not treat human cancer with interleukin-1 blockade?Gaucher iPSC-derived macrophages produce elevated levels of inflammatory mediators and serve as a new platform for therapeutic development.Requirement of the inducible nitric oxide synthase pathway for IL-1-induced osteoclastic bone resorption.Preclinical animal models of multiple myelomaBlocking interleukin-1β in acute and chronic autoinflammatory diseases.
P2860
Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors
description
im Juli 1996 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 July 1996
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в липні 1996
@uk
name
Modulation of osteoclast-activ ...... erent interleukin-1 inhibitors
@en
Modulation of osteoclast-activ ...... erent interleukin-1 inhibitors
@nl
type
label
Modulation of osteoclast-activ ...... erent interleukin-1 inhibitors
@en
Modulation of osteoclast-activ ...... erent interleukin-1 inhibitors
@nl
prefLabel
Modulation of osteoclast-activ ...... erent interleukin-1 inhibitors
@en
Modulation of osteoclast-activ ...... erent interleukin-1 inhibitors
@nl
P2093
P1476
Modulation of osteoclast-activ ...... erent interleukin-1 inhibitors
@en
P2093
Cozzolino F
Dinarello CA
Lucibello M
P304
P407
P577
1996-07-01T00:00:00Z